Trombodynamics Method in the Assessment of Coagulation Parameters in Psychopharmacotherapy of Endogenous Mental Disorders

Background: currently, it has been proven that the pathogenesis of endogenous mental disorders is associated with the process of neuroinflammation in the brain of patients. It is also known that chronic neuroinflammation, accompanied by a violation the permeability of the blood-brain barrier. It is accompanied by the activation of platelets that generate procoagulant microparticles, which leads to a disturbance of the hemostasis system, causing an increase in blood clotting in patients. Objective: to investigate the dynamics of procoagulant activity of blood in patients with endogenous mental disorders before and after psychopharmacotherapy.

Patients and methods: the study included 185 patients aged 16 to 64 years with the following mental disorders: schizophrenia with attack-like/attack-progressive/continuous type of course (F20.00–2), affective disease (F31.1–5; F32.0–3; F33.0–3), schizotypal disorder with affective fluctuations (F21.3–4). The thrombodynamic test (TD) was performed on T-2 Trombodynamis device according to the manufacturer’s instructions (Hemacore LLC, Moscow, Russia). All patients received standard pharmacotherapy according to their condition.

Results: a significant decrease of procoagulant activity of spontaneous clots in the patients’ blood after psychopharmacological treatment is observed. Our data on the positive dynamics of changes in the values of TD test’s indicators in most of the examined patients suggest that a decrease in the coagulation activity of the patients’ blood as a result of treatment may be associated with the anti- inflammatory effect of antipsychotics and antidepressants.

Conclusion: for the first time, it was shown that there is a positive dynamic in changing the values of the main parameters of the TD test in most patients with endogenous mental diseases. The results of TD tests can be the basis for monitoring the response to therapy.

1. Kostyukova AB, Mosolov SN. Neuroinflammatory hypothesis of schizophrenia and some new therapeutic approaches. Modern therapy of mental disorders. 2013;(4):8–17. (In Russ.).

2. Brusov OS, Oleichik IV, Faktor MI, Karpova NS, Sizov SV, Yunilaynen OA. Thrombodynamic parameters of hypercoagulability in patients with affective disorder and schizophrenia in a state of exacerbation. S.S. Korsakov Journal of Neurology and Psychiatry/“ Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova”. 2018;118(10):41–45. (In Russ.).

3. Brusov OS, Matveev IA, Kirillov PS, Faktor MI, Karpova NS, Vasilyeva EF, Katasonov AB, Zozulya SA, Klushnik TP. Risk assessment of thrombotic events in patients with schizophrenia and schizoaffective disorders in the acute state: the «fibrinodynamicsТМ » technology. S.S. Korsakov Journal of Neurology and Psychiatry/“Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova”. 2017;117(11):91–100. (In Russ.).

4. Brusov OS, Simashkova NV, Karpova NS, Factor MI, Nikitina SG. Thrombodynamic parameters of hypercoagulation of blood in children with childhood autism and schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry/“Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova”. 2019;119(1):59–63. (In Russ.). DOI: 10.17116/jnevro201911901159

5. Dietrich-Muszalska A, Wachowicz B. Platelet haemostatic function in psychiatric disorders: effects of antidepressants and antipsychotic drugs. The World Journal of Biological Psychiatry. 2017;18(8):564–574. DOI: 10.3109/15622975.2016.1155748

6. Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, Kasai M, Utsumi H, Kanba S. Anti-inflammatory properties of antipsychotics via microglia modulation: are antipsychotics a «fire extinguisher» in the brain of schizophrenia? Mini Reviews in Medical Chemistry. 2011;11(7):565–574. DOI: 10.2174/138955711795906941

7. Karpova NS, Brusov OS, Oleichik IV, Simashkova NV, Faktor MI, Levchenko NS, Nikitina SG. Hypercoagulation of Blood Plasma with Spontaneous Clots as a Biological Marker of the Severity of Mental Disorders. Psychiatry (Moscow). 2019;17(4):81–89. (In Russ.). DOI: 10.30629/2618-6667-2019-17-4-81-89S

8. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 2001;49(1–2):1–52. DOI: 10.1016/s0920-9964(01)00163-3

9. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry. 2007;64(5):521–529. DOI: 10.1001/archpsyc.64.5.521

10. Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Moller HJ, Klauss V, Schwarz MJ, Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010;121(1–3):118–124. DOI: 10.1016/j.schres.2010.04.015

11. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin. Neuropharmacol. 2008;31(5):287–292. DOI: 10.1097/WNF.0b013e3181593d45

12. Kato TA, Monji A, Yasukawa K, Mizoguchi Y, Horikawa H, Seki Y, Hashioka S, Han YH, Kasai M, Sonoda N, Hirata E, Maeda Y, Inoguchi T, Utsumi H, Kanba S. Aripiprazole inhibits superoxide generation from phorbolmyristate-acetate (PMA) stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia. Schizophr Res. 2011;129(2–3):172–82. DOI: 10.1016/j.schres.2011.03.019

13. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scandinavian J. of Immunity. 2007;66:159–165. DOI: 10.1111/j.1365-3083.2007.01984.x